Oxaliplatin, 5-FU, Folinic Acid as First-line Palliative Chemotherapy in Elderly Patients with Metastatic or Recurrent Gastric Cancer / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 99-103, 2007.
Artículo
en Inglés
| WPRIM
| ID: wpr-86058
ABSTRACT
PURPOSE:
We investigated the efficacy and safety of a combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line palliative chemotherapy for elderly patients with metastatic or recurrent gastric cancer. MATERIALS ANDMETHODS:
The study patients were chemotherapy-naive patients (> 65 years old) with histologically confirmed, metastatic or recurrent gastric cancer. Chemotherapy consisted of oxaliplatin 100 mg/m2 and FA 100 mg/m2 (2-hour infusion), and then 5-FU 2400 mg/m2 (46-hour continuous infusion) every 2 weeks.RESULTS:
A total of 37 patients were studied between April 2004 and October 2006. Of the 34 evaluable patients, none achieved a complete response (CR) and 14 achieved a partial response (PR), resulting in an overall response rate of 41.2%. The median time to progression (TTP) was 5.7 months (95% CI 4.2~6.3 months) and the median overall survival (OS) was 9.8 months (95% CI 4.4~12.0 months). The main hematologic toxicities were anemia and neutropenia, which were observed in 56.7% and 32.4% of the patients, respectively. Grade 3/4 neutropenia was observed in 8.1% of the patients. None of the patients experienced febrile neutropenia. Peripheral neuropathy occurred in 35.1% of the patients and all were grade 1/2.CONCLUSION:
This oxaliplatin/5-FU/FA regimen showed good efficacy and an acceptable toxicity profile in elderly patients with metastatic or recurrent gastric cancer.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias Gástricas
/
Leucovorina
/
Enfermedades del Sistema Nervioso Periférico
/
Quimioterapia
/
Neutropenia Febril
/
Fluorouracilo
/
Anemia
/
Neutropenia
Límite:
Anciano
/
Humanos
Idioma:
Inglés
Revista:
Cancer Research and Treatment
Año:
2007
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS